Visionflex Group Limited · ASX:VFX
Visionflex — H1 FY25 Earnings Presentation
20 slides from Visionflex's earnings presentation, Feb 21, 2025
Slide 1: H1 FY25 Results Investor Presentation
ASX:VFX H1 FY25 Results Investor Presentation 21 FEBRUARY 2025 This announcement was approved for release by the Board of Directors. H1 FY25 RESULTS INVESTOR PRESENTATION / FEBRUARY 2025 / 1
Slide 2: The Visionflex mission
The Visionflex mission Empowering health practitioners globally with cutting edge technologies to elevate patient outcomes. PRO PRIETARY PRO PRIETARY H ARD W ARE SO FTW ARE TH IRD PARTY H ARD W ARE Visionflex proprietary hardware and software connect a range of third-party medical devices to empower
Slide 3: Hardware
Hardware Visionflex hardware enables health practitioners to virtually conduct medical examinations with confidence and serves as a foundational step for establishing long term software subscriptions. PERIPHERALS + SOFTWARE DEVICE + PERIPHERALS + SOFTWARE MEDICAL CART + PERIPHERALS + SOFTWARE Mobile
Slide 4: Proprietary Software (Virtual Care Platform)
Proprietary Software (Virtual Care Platform) A virtual healthcare platform allowing practitioners to virtually examine, diagnose, monitor, and treat patients. Perform collaborative, clinical, evidence-based consultations between clinicians A user-friendly video conferencing platform that delivers he
Slide 5: Revenue Streams
Revenue Model Offering Core HARDWARE SOFTWARE Key Product / Services Revenue RECURRING REVENUE Streams UPFRONT / ONE-OFF $5k – $30k per unit depending on solution ~$5k per annum for annual software license margin 60-65% GP margin 90-95% GP margin GP Revenue Repeat Each new software license typically
Slide 6: H1 FY25 Highlights
H1 FY25 Highlights H1 FY25 RESULTS INVESTOR PRESENTATION / FEBRUARY 2025 / 66
Slide 7: H1 FY25 Financial Summary
H1 FY25 Financial Summary Note: Presented below is the Visionflex division (including corporate costs), key financial metrics. For a detailed group statutory Profit and Loss (including businesses exited during the year), refer to the Appendix 4D & H1 FY25 Interim Financial Report – 31 December 2024
Slide 8: Strategy Summary and Progress in H1 FY25
Strategy Summary and Progress in H1 FY25 • Multiple trial sites and early penetration into new markets underpinning material future opportunity: – Spark Health (NZ, subsidiary of one NZ largest telco companies): National r eseller agreement to deliver virtual care solutions in NZ; first orders deliv
Slide 9: Strategic Priorities - H2 FY25
Strategic Priorities - H2 FY25 1 Deliver profitable growth: 2 Transition to recurring revenue via SaaS : • Targeting to be underlying run rate EBITDA positive in Q4 • Transition to SaaS pricing delivering growth in annual FY25. recurring revenue (ARR) with 114% growth since the pcp. • Qualified pipe
Slide 10: H1 FY25 Financial Overview
H1 FY25 Financial Overview H1 FY25 RESULTS INVESTOR PRESENTATION / FEBRUARY 2025 / 1 10 0
Slide 11: Financial Dashboard
Financial Dashboard Growing international Variance driven by large revenue contribution Hardware sales in H1 FY24 and H2 FY24. VFX have several enterprise deals expected to Revenue land in H2 FY25 Revenue (By Type) (By Region) ~23% ~86% ARR Underlying Growth EBITDA H1 FY25 RESULTS INVESTOR PRESENTAT
Slide 12: Profit & Loss
Profit & Loss •1 Strong growth in recurring subscription Strong growth in recurring software licenses underpin rationale for transitioning revenues validating progressive shift business model and future profitably, Delayed enterprise hardware sales in H1 towards a sustainable ARR business. FY25 are
Slide 13: Balance Sheet
Balance Sheet Material improvement in strength of balance sheet provides operating flexibility to pursue growth opportunities 1 •1 $2.4m cash provides sufficient headroom to deliver growth objectives and reach run rate EBITDA positivity in Q4 FY25. 2 •2 Income tax refund (R&D tax receivable 3 foreca
Slide 14: Cash Flow Statement
Cash Flow Statement Near term operating cashflow driven by large enterprise hardware contracts, however over time recurring software revenue will underpin a stabilisation in operating cashflows •1 Decline in customer receipts in-line with corresponding reduction in revenue and 1 delayed enterprise s
Slide 15: Market Segments
Market Segments H1 FY25 RESULTS INVESTOR PRESENTATION / FEBRUARY 2025 / 1 15 5
Slide 16: Key customers by market segment
Key customers by market segment PRIMARY HEALTH NETWORKS AGED CARE CORPORATES LOCAL HEALTH DISTRICTS INDIGENOUS HEALTH & OTHER HEALTH BODIES INTERNATIONAL H1 FY25 RESULTS INVESTOR PRESENTATION / FEBRUARY 2025 / 16
Slide 17: Expansion in key market segments
Expansion in key market segments INDIGENOUS HEALTH AGED/HOME CARE RESOURCE SECTOR CORRECTIONAL FACILITIES • NACCHO is the national peak body • Residential Aged Care: There are 886 • Global operations in remote and • There are 116 custodial correctional representing 145 Aboriginal Health organisation
Slide 18: International expansion
International expansion AGENCY 2 PARTNERSHIPS Visionflex products sold to all key UK & Europe global jurisdictions - Americas, Europe and Asia. $0.3m of sales to customers in 6 overseas countries in 1H FY25. AGENCY 1 PARTNERSHIPS AGENCY 3 Growth opportunities through PARTNERSHIPS Americas strategic
Slide 19: Important notices
Important notices This H1 FY25 Results Investor Presentation (Presentation) has been prepared by Visionflex Group Limited ACN 138 897 533 (ASX:VFX) (Company) & is rounding. Accordingly, the actual calculations of these figures may differ from the figures set out in this Presentation. dated 21 Februa
Slide 20: Visionflex Group Limited
Visionflex Group Limited Unit 1, 8 Prosperity Parade, Warriewood NSW 2102 VFX-GROUP.COM Joshua Mundey CHIEF EXECUTIVE OFFICER E: jmundey@visionflex.com H1 FY25 RESULTS INVESTOR PRESENTATION / FEBRUARY 2025 / 220 0